SB 258719 hydrochloride

Discontinued Product

2726 has been discontinued.

View all 5-HT<sub>7</sub> Receptors products.
Description: Selective 5-HT7 antagonist
Chemical Name: 3-Methyl-N-[(1R)-1-methyl-3-(4-methyl-1-piperidinyl)propyl]-N-methylbenzenesulfonamide hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations (3)
Reviews
Literature (2)

Biological Activity for SB 258719 hydrochloride

SB 258719 hydrochloride is a selective 5-HT7 receptor antagonist that displays > 100-fold selectivity over a range of other receptors. Reverses the hypothermic effect of 5-CT in mice following i.p. administration.

Licensing Information

Sold for research purposes under agreement from GlaxoSmithKline

Compound Libraries for SB 258719 hydrochloride

SB 258719 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for SB 258719 hydrochloride

M. Wt 374.97
Formula C18H30N2O2S.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 1217674-10-6
PubChem ID 56972181
InChI Key UIZKHTBWJSUGOV-UNTBIKODSA-N
Smiles O=S(C1=CC(C)=CC=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for SB 258719 hydrochloride

References for SB 258719 hydrochloride

References are publications that support the biological activity of the product.

Forbes et al (1998) (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist. J.Med.Chem. 41 655 PMID: 9513592

Thomas et al (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br.J.Pharmacol. 124 1300 PMID: 9720804

Guscott et al (2003) The hypothermic effect of 5-CT in mice is mediated through the 5-HT7receptor. Neuropharmacology 44 1031 PMID: 12763096

View Related Products by Target

View Related Products by Product Action

View all 5-HT7 Receptor Antagonists

Keywords: SB 258719 hydrochloride, SB 258719 hydrochloride supplier, Selective, 5-HT7, antagonists, Serotonin, Receptors, 5-Hydroxytryptamine, SB258719, hydrochloride, GlaxoSmithKline, GSK, 2726, Tocris Bioscience

3 Citations for SB 258719 hydrochloride

Citations are publications that use Tocris products. Selected citations for SB 258719 hydrochloride include:

Johnson et al (2011) Serotonin receptor activity is necessary for olfactory learning and memory in Drosophila melanogaster. Neuroscience 192 372 PMID: 21749913

Domínguez-Soto (2017) Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis. Sci Rep 7 14761 PMID: 29116249

Zhao et al (2015) Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system. Front Synaptic Neurosci 5 9043 PMID: 25761874


Reviews for SB 258719 hydrochloride

There are currently no reviews for this product. Be the first to review SB 258719 hydrochloride and earn rewards!

Have you used SB 258719 hydrochloride?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.